As part of the health community, the life sciences sector in the UK wants to play as big a role as possible in tackling COVD-19 – both in the search for effective diagnostics and treatments and by supporting patients, the NHS and Government across the UK.
We’re in regular contact, both with our members and the Government about any impact that the coronavirus could have on medicine supply in the UK.
There are significant global efforts underway to diagnose, treat and prevent infections from the virus. Pharmaceutical companies are working globally to combat COVID-19.
This information is updated regularly, however it does not supersede advice or information provided by the relevant Government bodies and regulators.
The Government has confirmed that COVID-19 testing capacity will increase.
Historically the process of finding a new vaccine has been long and complex. But as organisations work together and new technologies like AI emerge, in some cases we might be able to develop them faster.
The ABPI has produced this sourcebook to support pharmaceutical companies in working successfully and collaboratively with patients and patient organisations.
01 April 2020
Four trade bodies representing the life sciences sector have released a joint statement on testing kits for COVID-19.
19 March 2020
The Department of Health and Social Care has published the latest Voluntary Scheme sales data for Q4 2019 which brings the total branded growth rate for 2019 versus 2018 to 1.6%.
16 March 2020
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to this outbreak.
11 March 2020
The Chancellor Rishi Sunak has delivered his first Budget, and the first for the Government following last year's General Election.
05 March 2020
The balance the Chancellor needs to strike in delivering his first Budget on Wednesday has been made even tougher by the need to prioritise measures to tackle coronavirus.
20 February 2020
Professor Derralynn Hughes is Professor of experimental haematology based at the Royal Free London NHS Foundation Trust and University College London, and an expert on a group of rare diseases called lysosomal disorders.